ASCO Announces Election Candidates; Voting Opens on November 3
The ASCO Nominating Committee has selected 15 distinguished members as candidates for open leadership positions within the Society. Voting Members are urged to vote in the election beginning November 3, 2021. Voting will close on December 7, 2021.
This year’s diverse slate of ASCO candidates reflects significant innovations that were adopted by the membership to increase diversity and inclusivity in ASCO governance. Amendments to the ASCO Bylaws were passed by the members in the 2020 election and went into effect this year. As a result, ASCO members will notice two significant changes to this year’s election:
- Greatly expanded eligibility for voting and service: More than 12,000 additional ASCO members are eligible to vote in this year’s election for the first time. Any member with a doctoral-level degree, regardless of membership category, is eligible to vote in the ASCO election, serve on the ASCO Board of Directors, and serve on the ASCO Nominating Committee. This means approximately 83% of all ASCO members are eligible to vote. Voting Members must be in good standing as of October 18, 2021, to be eligible to vote in this year’s election.
- Greater opportunity for service and diversity in the role of President-Elect: This year there is one name on the ballot for President-Elect. The nomination was recommended by the Nominating Committee and approved by the Board of Directors as set out in the ASCO Bylaws. Under this system, more of the prior Board members are engaged and willing to serve as President-Elect. The Nominating Committee and Board are able to support diversity in the role of President-Elect from year to year. Over the long term, the ASCO Presidency can reflect the diversity of the oncology community in terms of specialty, professional setting, geography, demographics, and other characteristics. Voting Members are able to vote in favor of the President-Elect candidate or write in an alternate candidate. The change applies only to the role of President-Elect; multiple candidates are nominated for open seats on the Board of Directors and the Nominating Committee.
These changes to the Society Bylaws were reviewed and approved by the Society Board of Directors and passed by a two-thirds majority of members voting in 2020. They are intended to increase diversity and member engagement in shaping the future of the organization.
Election results will be announced in mid-December 2021, and newly elected leaders will begin their terms in office in June 2022. Please contact ASCO Election staff with any questions.
President-Elect Candidate (one seat, 4-year term)
Dr. Schuchter is chief of the Division of Hematology-Oncology at the University of Pennsylvania, director of the Tara Miller Melanoma Center at Abramson Cancer Center, and the C. Willard Robinson Professor of Hematology-Oncology at the University of Pennsylvania School of Medicine. Dr. Schuchter served on the ASCO Board of Directors from 2009 to 2012. She has served on numerous ASCO committees, including terms as chair of Annual Meeting Scientific Program Committee, Cancer Research Committee, and Cancer Communications Committee, and as an editor on the Journal of Clinical Oncology Editorial Board. In 2019, she was recognized with the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award from Conquer Cancer, the ASCO Foundation.
Board of Directors – Designated Community Oncologist Candidates (one seat, 4-year term)
Dr. Hendricks is a practicing medical oncologist specializing in breast cancer genetics, screening, and treatment at Maryland Oncology Hematology PA. She is chair of the ABIM-ASCO Breast Cancer Exam Subcommittee, chair-elect of the Practice Quality Improvement Steering Group, past chair of the Government Relations Committee, and a member of Clinical Practice Committee and the Quality Training Program Steering Group, among other volunteer service. Dr. Hendricks was honored as Advocate of the Year by the Association for Clinical Oncology in 2019.
Dr. Patt is the executive vice president of Texas Oncology PA and a clinical professor at Dell Medical School at The University of Texas at Austin. She serves as president of the Texas Society of Clinical Oncology (an ASCO State Affiliate) and as editor in chief of JCO Clinical Cancer Informatics. Dr. Patt is a member of the ASCO Expert Panels on Systemic Therapy for Advanced HER2+ Breast Cancer and Brain Metastases and Telemedicine Standards, among other volunteer service. She is a past participant in the ASCO Leadership Development Program and a past recipient of a Young Investigator Award and a Merit Award from Conquer Cancer, the ASCO Foundation.
Board of Directors – Designated International Oncologist Candidates (one seat, 4-year term)
Dr. Asirwa is the chief oncologist and hematologist and the CEO/executive director of the International Cancer Institute in Kenya. He is a member of the ESMO/ASCO Task Force for Global Curriculum for Training in Medical Oncology, among other past volunteer appointments.
Dr. Mathias is a medical oncologist and director of NOB/Oncoclinicas in Brazil. She is a member of the ASCO International Quality Steering Group and Lung Cancer - Non-small Cell Metastatic Track of the Annual Meeting Scientific Program Committee, and past chair of the International Affairs Committee, among other past volunteer service.
Board of Directors – Designated Radiation Oncologist Candidates (one seat, 4-year term)
Dr. Diehn is an Associate Professor, Division Chief of Radiation and Cancer biology, and Vice Chair of Research in the Department of Radiation Oncology at Stanford University School of Medicine. He is a member of the ASCO Cancer Research Committee, the ASCO Plenary Series Scientific Review Committee (Lung Cancer Track) and serves on the JCO Precision Oncology editorial board, among other past volunteer appointments. Dr. Diehn is a past participant in the ASCO Leadership Development Program.
Dr. Winkfield is the executive director of the Meharry-Vanderbilt Alliance and a radiation oncologist at Vanderbilt University Medical Center. She is chair of the ASCO Diversity and Inclusivity Task Force, a member of the ASCO Government Relations Committee and the ASCO-ACCC Collaboration to Increase Participation of Racial & Ethnic Minority Populations in Cancer, and an associate editor for Cancer.Net, ASCO’s patient information website. Dr. Winkfield is a past participant in the ASCO Leadership Development Program and was recently appointed by President Joe Biden to serve on the National Cancer Advisory Board.
Board of Directors – Undesignated Member Candidates (one seat, 4-year term)
Dr. Henry is an associate professor, disease lead for breast oncology, co-chair of the cancer control and prevention clinical research team, and assistant director of training, education and career development at the University of Michigan Rogel Cancer Center. She serves as associate division chief for clinical research and section head of breast oncology in the Division of Hematology/Oncology at the University of Michigan Medical School. Among her volunteer appointments, she is a member and past chair of the ASCO Annual Meeting Scientific Program Committee, co-chair of the Patient/Disease Factors and Recurrence Risk in Breast Cancer Expert Panel and the Use of Tumor Biomarkers in Advanced Breast Cancer Expert Panel, and a member of the Conquer Cancer Grants Selection Committee. She serves on the editorial board of Cancer.Net, ASCO’s patient information website. She is a past participant in the ASCO Leadership Development Program and past recipient of a Young Investigator Award and a Merit Award from Conquer Cancer, the ASCO Foundation.
Dr. Partridge is a practicing medical oncologist and clinical researcher. She is vice chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as director of the Adult Survivorship Program and co-founder and director of the Program for Young Women with Breast Cancer. She is a professor at Harvard Medical School. Dr. Partridge has sought to reduce morbidity and mortality from cancer through innovative research, guideline development, dedicated educational efforts, mentoring junior colleagues, and direct patient care. She has led studies focused on cancer disparities, risk perceptions, decision-making, quality of life, adherence with anti-cancer therapy, and cancer survivorship care. She is particularly committed to research to reduce disparities in outcomes among young women with breast cancer. Dr. Partridge chaired the Center for Disease Control’s Advisory Committee on Breast Cancer in Young Women from 2010-2017. She is leading national clinical research endeavors as co-Chair of the Alliance for Clinical Trials in Oncology Breast Committee and a member of the NCI Breast Cancer Steering Committee. Dr. Partridge is a recipient of a Champions of Change award from the U.S. White House, the AACR Outstanding Investigator Award for Breast Cancer, and ASCO’s Ellen L. Stovall Award for Advancement of Cancer Survivorship Care from Conquer Cancer.
Nominating Committee – Designated Community Oncologist Candidates (one seat, 3-year term)
Dr. Ahluwalia is the chief of solid tumor medical oncology as well as chief scientific officer and deputy director of Miami Cancer Institute, and a professor of translational medicine at Herbert Wertheim College of Medicine, Florida International University. He is a member of the ASCO Plenary Series Review Committee and the Evidence-Based Medicine Committee, and serves as a specialty editor for central nervous system tumors for Cancer.Net, ASCO’s patient information website, among additional past volunteer service. Dr. Ahluwalia is a past participant in the ASCO Leadership Development Program.
Dr. Zuckerman is the system medical director of St. Luke’s Cancer Institute and focuses on GI medical oncology. He is an adjunct professor of medicine at University of Washington Medical School. He is a member of the ASCO Gastrointestinal Measures Panel and Joint Certifications Committee, and serves an Association External Liaisons representative, among additional past volunteer service, including as a past chair of the ASCO Clinical Practice Committee. He lives in Boise, ID with his wife and three children.
Nominating Committee – Undesignated Member Candidates (two seats, each a 3-year term)
Dr. Friese is the associate director of cancer control and population sciences at the University of Michigan Rogel Cancer Center, director of the Center for Improving Patient and Population Health at the University of Michigan School of Nursing, the Elizabeth Tone Hosmer Professor of Nursing at the University of Michigan, and a professor at the University of Michigan School of Public Health. He was appointed by President Biden to a six-year term on the National Cancer Advisory Board. He is a member of the Health Services Research and Quality Improvement track of the ASCO Annual Meeting Education Committee and a member of the Oncology Clinician Well-Being Task Force, among additional past volunteer service.
Dr. Shroff is an associate professor of medicine (tenure track), chief of the Section of GI Medical Oncology, leader of the University of Arizona Cancer Center GI Clinical Research Team, director of the Clinical Trials Office, associate dean of clinical and translational research at UA College of Medicine-Tucson, an associate professor of cancer biology-GIDP, and medical director of the Arizona Clinical Trials Network (ACTN) at the University of Arizona Cancer Center. She serves as co-chair of the ASCO Gastrointestinal Guideline Advisory Group and a member of the Systemic Therapy for Advanced Hepatocellular Carcinoma Expert Panel, track leader of the Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary track of the Annual Meeting Education Committee, the Gastrointestinal Cancers Symposium Leadership Committee, and the ASCO Daily News Expert Panel, among additional past volunteer service. She is currently participating in the ASCO Leadership Development Program. Dr. Shroff is a past recipient of a Young Investigator Award and Merit Award from Conquer Cancer, the ASCO Foundation.
Dr. Smith is an associate professor, thoracic oncologist and palliative medicine physician at the Mount Sinai Tisch Cancer Center at the Icahn School of Medicine at Mount Sinai. She is a member of the ASCO Joint Certifications Committee, Quality Publications Task Force, and Quality Care Symposium Planning Committee, and serves as a specialty editor for Clinical Cancer Advances, among additional past volunteer service. Dr. Smith is a past participant in the ASCO Leadership Development Program.
Dr. Traina is an Associate Attending in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, where she also serves as Vice Chair, Oncology in the Department of Medicine. She is an Associate Professor at Weill Cornell Medical College and a special contributing faculty member at Gerstner Sloan Kettering Graduate School. She is immediate past chair of the ASCO Membership Advisory Committee and co-chair of the Breast Cancer Guideline Advisory Group, among additional past volunteer service. She is a graduate of the ASCO Leadership Development Program and a recent member of the ASCO Road to Recovery Task Force, which published learnings from the COVID-19 experience to improve clinical research and cancer care during the pandemic. She has served on the Breast Cancer Scientific Committee for past ASCO Annual Meetings, mentored IDEA award recipients, contributes to ASCO-SEP educational content and is a supporter of Conquer Cancer, the ASCO Foundation.